A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 19,588 shares of BMY stock, worth $1.14 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
19,588
Previous 20,198 3.02%
Holding current value
$1.14 Million
Previous $838,000 20.88%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$39.66 - $51.75 $24,192 - $31,567
-610 Reduced 3.02%
19,588 $1.01 Million
Q2 2024

Jul 17, 2024

SELL
$40.25 - $52.99 $87,101 - $114,670
-2,164 Reduced 9.68%
20,198 $838,000
Q1 2024

Apr 23, 2024

SELL
$47.98 - $54.4 $508,540 - $576,585
-10,599 Reduced 32.16%
22,362 $1.21 Million
Q4 2023

Feb 01, 2024

SELL
$48.48 - $57.85 $671,690 - $801,511
-13,855 Reduced 29.59%
32,961 $1.69 Million
Q3 2023

Nov 03, 2023

SELL
$57.89 - $64.73 $342,361 - $382,813
-5,914 Reduced 11.22%
46,816 $2.72 Million
Q2 2023

Aug 01, 2023

SELL
$63.71 - $70.74 $40,455 - $44,919
-635 Reduced 1.19%
52,730 $3.37 Million
Q1 2023

May 02, 2023

SELL
$65.71 - $74.53 $84,568 - $95,920
-1,287 Reduced 2.35%
53,365 $3.7 Million
Q4 2022

Mar 02, 2023

BUY
$68.48 - $81.09 $97,584 - $115,553
1,425 Added 2.68%
54,652 $3.93 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $114,224 - $135,258
-1,668 Reduced 3.04%
53,227 $3.9 Million
Q3 2022

Oct 25, 2022

SELL
$0.13 - $76.84 $25 - $15,291
-199 Reduced 0.36%
54,895 $3.9 Million
Q2 2022

Jul 26, 2022

BUY
$72.62 - $79.98 $87,361 - $96,215
1,203 Added 2.23%
55,094 $4.24 Million
Q1 2022

Apr 13, 2022

BUY
$61.48 - $73.72 $342,320 - $410,472
5,568 Added 11.52%
53,891 $3.94 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $10,726 - $12,504
-200 Reduced 0.41%
48,323 $3.01 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $108,340 - $126,906
-1,831 Reduced 3.64%
48,523 $2.87 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $219,842 - $239,408
3,551 Added 7.59%
50,354 $3.37 Million
Q1 2021

Apr 14, 2021

SELL
$59.34 - $66.74 $499,642 - $561,950
-8,420 Reduced 15.25%
46,803 $2.96 Million
Q4 2020

Jan 14, 2021

SELL
$57.74 - $65.43 $164,847 - $186,802
-2,855 Reduced 4.92%
55,223 $3.43 Million
Q3 2020

Oct 15, 2020

SELL
$57.43 - $63.64 $101,363 - $112,324
-1,765 Reduced 2.95%
58,078 $3.5 Million
Q2 2020

Jul 30, 2020

SELL
$54.82 - $64.09 $22,366 - $26,148
-408 Reduced 0.68%
59,843 $3.52 Million
Q1 2020

Apr 15, 2020

SELL
$46.4 - $67.43 $19,580 - $28,455
-422 Reduced 0.7%
60,251 $3.36 Million
Q4 2019

Jan 22, 2020

BUY
$49.21 - $64.19 $1.48 Million - $1.94 Million
30,151 Added 98.78%
60,673 $3.9 Million
Q3 2019

Nov 05, 2019

BUY
$42.77 - $50.71 $100,894 - $119,624
2,359 Added 8.38%
30,522 $1.55 Million
Q2 2019

Aug 09, 2019

SELL
$44.62 - $49.34 $1,829 - $2,022
-41 Reduced 0.15%
28,163 $1.28 Million
Q1 2019

Apr 08, 2019

SELL
$45.12 - $53.8 $62,536 - $74,566
-1,386 Reduced 4.68%
28,204 $1.35 Million
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $110,392 - $143,152
-2,264 Reduced 7.11%
29,590 $1.54 Million
Q2 2018

Aug 07, 2018

SELL
$50.53 - $62.98 $98,331 - $122,559
-1,946 Reduced 5.76%
31,854 $1.76 Million
Q1 2018

Apr 20, 2018

SELL
$59.92 - $68.98 $52,430 - $60,357
-875 Reduced 2.52%
33,800 $2.14 Million
Q4 2017

Feb 08, 2018

SELL
$59.94 - $65.35 $39,860 - $43,457
-665 Reduced 1.88%
34,675 $2.13 Million
Q3 2017

Oct 27, 2017

BUY
$55.23 - $63.74 $17,949 - $20,715
325 Added 0.93%
35,340 $2.25 Million
Q2 2017

Aug 07, 2017

BUY
N/A
35,015
35,015 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Loring Wolcott & Coolidge Fiduciary Advisors LLP Portfolio

Follow Loring Wolcott & Coolidge Fiduciary Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.